UROLET MB URINARY ANTISEPTIC, ANTISPASMODIC Tablets, Each tablet contains: Methenamine 81.6 mg, ...
FDA Drug Recall #D-0156-2017 — Class II — October 24, 2016
Recall Summary
| Recall Number | D-0156-2017 |
| Classification | Class II — Moderate risk |
| Date Initiated | October 24, 2016 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Burel Pharmaceuticals Inc |
| Location | Richland, MS |
| Product Type | Drugs |
| Quantity | 11,539 bottles |
Product Description
UROLET MB URINARY ANTISEPTIC, ANTISPASMODIC Tablets, Each tablet contains: Methenamine 81.6 mg, Monobasic Sodium Phosphate 40.8 mg, Phenyl Salicylate 36 mg, Methylene Blue, 10.8 mg; Hyoscyamine Sulfate, 0.12 mg, (a) 30 count (NDC 35573-302-30) and (b) 100 count bottles (NDC 35573-302-10), Rx only, Manufactured for: BUREL PHARMACEUTICALS, Richland, MS
Reason for Recall
CGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failures
Distribution Pattern
Nationwide
Lot / Code Information
(a) LOT # 28981501, EXP 8/17, NDC 35573-302-30; (b) LOT # 28981501, EXP 8/17, LOT # 28981601, EXP 4/18, NDC 35573-302-10
Other Recalls from Burel Pharmaceuticals Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0162-2017 | Class II | Phenazopyridine Hydrochloride Tablets, USP, 200... | Oct 24, 2016 |
| D-0159-2017 | Class II | AZUPHEN MB URINARY ANTISEPTIC Capsules, Each ca... | Oct 24, 2016 |
| D-0161-2017 | Class II | Phenazopyridine Hydrochloride Tablets, USP, 100... | Oct 24, 2016 |
| D-0157-2017 | Class II | URAMIT MB URINARY ANTISEPTIC Capsules, Each cap... | Oct 24, 2016 |
| D-0155-2017 | Class II | Hyolev MB URINARY ANTISEPTIC Tablets, Each tabl... | Oct 24, 2016 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.